Rodman & Renshaw Reiterate Market Rating And Price Target On Idera Pharmaceuticals

by BenzingaStaffB, Benzinga Staff Writer
July 22, 2011 11:35 AM | 12 seconds read |
According to Rodman & Renshaw, Idera Pharmaceuticals IDRA, PT and market rating are reiterated. Rodman & Renshaw are maintaining their Price Target of $4 and their rating of Outperform. Idera Pharmaceuticals closed yesterday at $1.80.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Analyst ColorReiterationAnalyst RatingsBiotechnologyHealth CareRodman & Renshaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!